Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Oxford Immunotec, Qiagen settle patent litigation

Executive Summary

Oxford Immunotec Global PLC and Qiagen NV have settled patent infringement litigation surrounding Qiagen's QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus tests for tuberculosis. Under the settlement, Oxford received a payment of $27.5mm and granted Qiagen a royalty-free, non-exclusive license extending to current and future customers of the products. Qiagen gained the QuantiFERON in vitro diagnostic technology through its $355mm acquisition of Cellectis in 2011. The platform can provide information on the activity of the cell-mediated function of the immune system from whole blood samples.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register